Sort by
Refine Your Search
-
at the University of Birmingham is pleased to offer a Part-Time Research Fellow post funded through the NIHR DEMCOMM Fellowship Programme. This post supports a motivated qualitative researcher to contribute
-
, driving cutting-edge research at the intersection of metabolomics, human health, and toxicology. This exciting role offers the opportunity to contribute to major EU-funded research programmes, including
-
: 21st August 2025 Background To create and contribute to the creation of knowledge by undertaking advanced analysis and validation experiments within the MRC BioFlare research programme: Although outcomes
-
to the creation of knowledge by undertaking a specified range of activities within two impactful applied health research programmes: DEKODE – a digital quality improvement initiative improving outcomes in diabetes
-
requirements and use resources effectively. Understanding of and ability to contribute to broader management/administration processes. Contribute to the planning and organising of the research programme and/or
-
will lead a project funded by the Grace Kelly Cancer Childhood Trust to test the performance of this tool, further develop and improve the tool, increase the number and range of tumours the programme
-
July 2025 Background To create and contribute to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Role
-
contribute to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Our international group of highly motivated and
-
introducing new group members to all aspects of their role Maintain a high level of knowledge of the immediate and surrounding literature for both your own project and those more widely in the group Plan
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor